August 2021 Volume 7 Issue 10

August 2021

Volume 7, Issue 10

This issue explores hematologic conditions in athletes, a blue top tube shortage, and more.

Table of Contents

August 2021 Issue

You Make the Call

Reader Responses: How would you manage this patient with T-cell large granular lymphocytic leukemia?

Monday, August 2nd, 2021
Here’s how readers responded to a You Make the Call question about management of a patient with T-cell large granular lymphocytic leukemia. Disclaimer: ASH does...

Marrow or Peripheral Blood for Allogeneic Transplant: Are We Ignoring the Data?

Monday, August 2nd, 2021
Here, Jennifer Saultz, DO, and Eneida Nemecek, MD, MBA, reflect on the debate over the optimal graft source for allogeneic hematopoietic cell transplantation, in...

Sex Cells: The Forgotten Biological Variable

Monday, August 2nd, 2021
The preponderance of the recently discovered COVID-19 vaccine–induced thrombotic thrombocytopenia (VITT) in women prompted several colleagues to reach out to me, a self-proclaimed “women’s...

Singing the Blues for Blue Top Tubes

Monday, August 2nd, 2021
Here, Mark A. Crowther, MD, and Steven L. Allen, MD, discuss the recent shortages of blue top tubes and how hematologists can “choose wisely”...

August 2021 Issue

Post-Transplant High-Dose Chemotherapy Increases Risk of Toxicities in Older Patients with Lymphoma

Monday, August 2nd, 2021
Most patients with lymphoma who are over age 60 experience cardiovascular toxicities with high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT), but these patients...

Pain, Comorbidities Increase Risk of Severe COVID-19 in Patients with SCD

Monday, August 2nd, 2021
Research published in Blood Advances found patients with sickle cell disease (SCD) and a history of pain and renal and heart/lung comorbidities have a...
The Society Pages

ASH Remembers Joel S. Bennett, Cancer Researchers Win Damon Runyon Physician-Scientist Training Awards, and...

Monday, August 2nd, 2021
Remembering Joel S. Bennett (1942 – 2021) Joel S. Bennett, MD, died of pancreatic cancer on June 21, 2021, at the age of 78.Aside from...

Post-Transplant High-Dose Chemotherapy Increases Risk of Toxicities in Older Patients With Lymphoma

Monday, August 2nd, 2021
Most patients with lymphoma who are over age 60 experience cardiovascular toxicities with high-dose chemotherapy and autologous hematopoietic cell transplantation (AHCT), but these patients...
ASH Directions

ASH Announces 2021 ASH Honorific Award Recipients, Issues New Guidance on Anticoagulation for Discharged...

Monday, August 2nd, 2021
Congratulations to the Recipients of the 2021 ASH Honorific Awards! The American Society of Hematology (ASH) has announced the recipients of its 2021 Honorific Awards,...

FDA Recommends Expanding Clinical Trial Eligibility for Patients with Incurable Cancers

Monday, August 2nd, 2021
The FDA has issued draft guidance for expanding investigational clinical trial options for patients with incurable cancers, encouraging sponsors to waive rules requiring patients...

Dabigatran Etexilate Approved for Children with VTE

Monday, August 2nd, 2021
The U.S. Food and Drug Administration (FDA) has approved dabigatran etexilate oral pellets for the treatment of children ages three months to 12 years...

One-Quarter of Americans Covered Under Medicaid During the Pandemic

Monday, August 2nd, 2021
A recent government report revealed that nearly 10 million Americans enrolled in Medicaid during the COVID-19 pandemic, with a record 80 million people –...
WIB_icon

Omidubicel Improves Outcomes, Reduces Hospital Stay for Patients with Hematologic Malignancies

Monday, August 2nd, 2021
Patients with hematologic malignancies who received umbilical cord blood transplantation with omidubicel engrafted faster, had fewer infections, and spent less time in the hospital, compared...

Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma

Monday, August 2nd, 2021
While treatment with ixazomib, lenalidomide, and dexamethasone (ixazomib-Rd) was shown to improve progression-free survival, recent long-term findings from the phase III TOURMALINE-MM1 trial published...

Comparing VTE Recurrence, Bleeding, and Death in Isolated Distal Versus Proximal DVT

Monday, August 2nd, 2021
Patients with isolated distal deep-vein thrombosis (DVT) and proximal DVT have similar long-term rates of venous thromboembolism (VTE) recurrence, bleeding, and death, according to...

Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM

Monday, August 2nd, 2021
Recent results suggest that in patients with relapsed multiple myeloma (MM), combination therapy consisting of carfilzomib and dexamethasone (Kd) plus isatuximab is associated with...

Ibrutinib Plus Venetoclax Shows Promise in Treatment-Naïve CLL

Monday, August 2nd, 2021
First-line combination therapy with ibrutinib and venetoclax was associated with higher rates of undetectable measurable residual disease (MRD), remission, and three-year progression-free survival (PFS)...

Orelabrutinib Receives Breakthrough Therapy Designation for Mantle Cell Lymphoma

Monday, August 2nd, 2021
The FDA has granted breakthrough therapy designation to the selective Bruton tyrosine kinase inhibitor orelabrutinib for the treatment of patients with relapsed/refractory mantle cell...

Asparaginase Erwinia Chrysanthemi Approved for Leukemia/Lymphoma

Monday, August 2nd, 2021
Asparaginase Erwinia chrysanthemi (recombinant)-rywn has been approved by the FDA as part of a treatment regimen for adult and pediatric patients with acute lymphocytic...

August 2021 Issue

Pulling Back the Curtain: Uma Borate, MD

Monday, August 2nd, 2021
In this edition, Uma Borate, MD, speaks about growing up in a household with extended family, including her “living legend” grandmother, and trying to...

The Eye of a Survivor

Monday, August 2nd, 2021
While cure remains a goal, unique issues arise when treating professional and amateur athletes for hematologic conditions. Athletic competition on an elite level depends on...

August 2021 Issue

You Make the Call

You Make the Call: How would you manage this patient with T-cell large granular...

Monday, August 2nd, 2021
This month, Richard Furman, MD, discusses management of a patient with T-cell large granular lymphocytic leukemia. And don't forget to check out next month's clinical...

Afibrinogenemia: A Rare, Often Overlooked Bleeding Disorder

Monday, August 2nd, 2021
Afibrinogenemia is a very rare, inherited blood disorder in which the blood does not clot normally because of a mutation that leads to the...

August 2021 Issue

On location

Investigating the Combination of Ivosidenib Plus Venetoclax and Azacitidine in IDH-Mutated Myeloid Malignancies

Monday, August 2nd, 2021
In a small study of patients with IDH1-mutated myeloid malignancies, treatment with ivosidenib plus venetoclax, with or without azacitidine, had an acceptable safety profile and led to high...
On location

Evaluating Two New Options for Hereditary Hemorrhagic Telangiectasia

Monday, August 2nd, 2021
At EHA2021 Virtual, researchers shared safety and efficacy findings of two agents for the treatment of the rare disease hereditary hemorrhagic telangiectasia (HHT): pazopanib...
On location

Ibrutinib Plus Rituximab Shows Efficacy in Indolent Mantle Cell Lymphoma

Monday, August 2nd, 2021
In the GELTAMO ICML-2015 study, treatment with frontline ibrutinib in combination with rituximab demonstrated high rates of efficacy in patients with indolent mantle cell...
On location

Evaluating a Response-Adapted Rituximab Approach for Patients With Follicular Lymphoma

Monday, August 2nd, 2021
In patients with follicular lymphoma (FL), standard rituximab maintenance produced better rates of progression-free survival (PFS) than an experimental response-adopted approach, according to results...
On location

Does Khorana Score Accurately Predict VTE in Patients With Uterine and Ovarian Cancer?

Monday, August 2nd, 2021
At the 2021 ASCO Annual Meeting, researchers shared results from two studies examining the Khorana score for predicting venous thromboembolism (VTE) in patients with...
On location

PDE9 Inhibitor Shows Promise as Monotherapy and With Hydroxyurea in Sickle Cell Disease

Monday, August 2nd, 2021
Data from two new studies indicated that daily dosing of the oral phosphodiesterase type 9 (PDE9) inhibitor IMR-687, at doses up to 200 mg,...
On location

Letermovir Prevents Cytomegalovirus Infection and Improves Survival Post-Transplant

Monday, August 2nd, 2021
Prophylactic treatment with letermovir improved overall survival (OS) and significantly decreased the incidence of clinically significant cytomegalovirus (CMV) infection in patients who underwent allogeneic hematopoietic cell...
On location

Venetoclax Added to Intensive Chemotherapy Is Safe, Effective in Relapsed/Refractory AML

Monday, August 2nd, 2021
In a study presented at EHA2021 Virtual, the annual congress of the European Hematology Association, adding short-term venetoclax to an intensive FLA-IDA chemotherapy regimen proved safe...